Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 5 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Prelude Therapeutics Inc | 230,000 | reported | 04 Feb 2026 | tx 14+1,093,137−36,062 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 04 Feb 2026 | GRANT_AWARD | Prelude Therapeutics Inc | 230,000 | 0.00 USD | deriv |
| 25 Mar 2025 | PURCHASE | Prelude Therapeutics Inc | 100,000 | 0.69 USD | |
| 04 Feb 2025 | GRANT_AWARD | Prelude Therapeutics Inc | 175,000 | 0.00 USD | deriv |
| 20 Dec 2024 | PURCHASE | Prelude Therapeutics Inc | 3,075 | 1.15 USD | first after silence |
| 23 Dec 2024 | PURCHASE | Prelude Therapeutics Inc | 60,000 | 1.37 USD | |
| 01 Mar 2024 | GRANT_AWARD | Prelude Therapeutics Inc | 150,000 | 0.00 USD | deriv |
| 07 Feb 2023 | GRANT_AWARD | Prelude Therapeutics Inc | 135,000 | 0.00 USD | deriv |
| 31 Mar 2022 | EXERCISE | Prelude Therapeutics Inc | 36,062 | 1.89 USD | |
| 01 Apr 2022 | EXERCISE | Prelude Therapeutics Inc | 36,062 | 0.00 USD | deriv |
| 15 Feb 2022 | GRANT_AWARD | Prelude Therapeutics Inc | 100,000 | 0.00 USD | deriv |
| 13 Dec 2021 | PURCHASE | Prelude Therapeutics Inc | 4,000 | 12.12 USD | first after silence |
| 14 Dec 2021 | PURCHASE | Prelude Therapeutics Inc | 4,000 | 11.60 USD | |
| 20 Jul 2021 | GRANT_AWARD | Prelude Therapeutics Inc | 95,000 | 0.00 USD | deriv |
| 29 Sept 2020 | PURCHASE | Prelude Therapeutics Inc | 1,000 | 19.00 USD |
2 purchases reported after at least 12 months of silence — most recent on 20 Dec 2024.